Advanced search
Publication Cover
Journal of Medical Economics Volume 24, 2021 - Issue 1
Submit an article Journal homepage
3,978
Views
7
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China

Xin Guana School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China;b Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, ChinaView further author information
,
Hongchao Lia School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China;b Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, ChinaView further author information
,
Xiaomo Xionga School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China;b Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, ChinaView further author information
,
Cike Pengc Eli Lilly China Drug Development and Medical Affairs Center, Shanghai, ChinaView further author information
,
Ning Wangc Eli Lilly China Drug Development and Medical Affairs Center, Shanghai, ChinaView further author information
,
Xiao Mac Eli Lilly China Drug Development and Medical Affairs Center, Shanghai, ChinaView further author information
&
Aixia Maa School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China;b Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 339-344 | Received 08 Oct 2020, Accepted 08 Feb 2021, Published online: 01 Mar 2021

References

  • Ferlay J, Soerjomataram I, Ervik M. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013.
  • Zheng R, Sun K, Zhang S, et al. Report of cancer epidemiology in China, 2015. Chin J Oncol. 2019;41:19–28.
  • Cai J, Cai S, Qin X, et al. Guideline for the diagnosis and comprehensive treatment of colorectal cancer with liver metastases (2016 edition). Chin J Dig Surg. 2016;36:858–869.
  • Chinese Society of Clinical Oncology (CSCO) Diagnosis and Treatment Guidelines for Colorectal Cancer Working Group. Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2019. Beijing: People's Medical Publishing House; 2019.
  • Xu RH, Li J, Bai Y, et al. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. 2017;10(1):22.
  • Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO Randomized Clinical Trial. JAMA. 2018;319(24):2486–2496.
  • Liu GG. China guidelines for pharmacoeconomic evaluation. Beijing, China: China Market Press; 2020.
  • Goldstein DA, Ahmad BB, Chen Q, et al. Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer. J Clin Oncol. 2015;33(32):3727–3732.
  • Tumeh JW, Shenoy PJ, Moore SG, et al. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer. Am J Clin Oncol. 2009;32(1):49–55.
  • Hoyle M, Peters J, Crathorne L, et al. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer. Value Health. 2013;16(2):288–296.
  • Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(6):619–629.
  • Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12:9.
  • Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95(6):683–690.
  • Jiangsu Public Resource Trading Platform. Platform JPRT. Part of the record purchase and the direct-linked network purchases drugs in Jiangsu Province. Nanjing; 2019. Available from: http://news.pharmnet.com.cn/news/2019/05/10/521748.html
  • Ministry of Human Resources and Social Security of the People's Republic of China (MoHRSS). Administration CMS. Notification about including 17 anti-cancer drugs into the national basic insurance, work-related accident insurance and maternity insurance. Beijing; 2018. Available from: http://www.gov.cn/xinwen/2018-10/10/content_5328891.htm
  • Shen L, Ying X, Li Q, et al. PCN67 – treatment patterns and economic burden of Chinese metastatic colorectal cancer patients: a retrospective study of electronic medical records from urban China. Value Health. 2018; 21:S23.
  • Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–312.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.